Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07131969

Transcriptional Analysis of Mechanisms in Liver Failure and Sepsis

Context Acute liver failure (ALF) is a life-threatening condition that occurs on the background of a healthy liver. The most common cause of acute liver failure in the UK is paracetamol overdose. Acute liver failure results from liver damage and activation of the body's inflammatory defences with subsequent damage to other organs including kidneys, lungs and heart. This often requires life support in an intensive care unit before liver transplantation (LT), the only currently available and effective rescue treatment for acute liver failure.

Challenge Patient factors and organ availability limit who can benefit from liver transplant. At present there are no effective alternative therapies for patients who do not get a liver transplant, and survival rates in these situations are poor. The underlying mechanisms of inflammation are poorly understood, thus therapies are limited.

Aim The investigators research aims to understand the mechanisms that underpin the inflammation seen in acute liver failure by studying the inflammatory cells in the blood and examining their cellular programmes. This will allow the investigators to identify pathways that are activated and understand how the liver and blood interact to spread inflammation around the body. The investigators aim to identify targets for disease-modifying therapies to avert the need for liver transplant.

Importance Understanding how the body responds to acute liver failure, and whether there are different patterns of inflammatory response, will enable trials of immune-modulating drugs to prevent the need for liver transplantation or prolong the time a patient can wait for an organ. This has the potential to help improve organ availability for other patients and save lives in acute liver failure.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospitals Birmingham, Birmingham, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • acute liver failure due to acetaminophen (paracetamol) overdose admitted to ICU
  • all cause sepsis admitted to ICU

Exclusion criteria

  • age <16y

Treatment and study plan

Blood Draw

Other

Venous blood sampling into Tempus tube for RNA-sequencing

Primary outcomes

  1. Mortality

    Time frame: From enrolment until at least 1-year

Secondary outcomes

  1. Transplant free survival

    Time frame: From enrolment to at least one year

    30-day and 1-year survival without transplant

  2. Length of stay - ICU and hospital

    Time frame: From enrolment

    Number of days stayed in ICU and in-hospital

  3. Transplant free mortality

    Time frame: From enrolment until death (at least until 1year)

    Death without transplant

Sponsors and collaborators

Lead sponsor

University of Cambridge

Other

Collaborators

  • European Society of Intensive Care Medicine

Registry information

Official study title

Transcriptional Analysis of Mechanisms and Predictors in Acute Liver Failure and Sepsis

Acronym: MAP-ALF

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Aug 20, 2025
Registry last updated
Aug 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.